Sarah Cohen, MD, is Vice President, Head of Clinical Development at Neogene Therapeutics. She is a physician-scientist experienced in drug development strategy from the pre-IND to first in human phase 1 and registrational phase 3 studies across multiple therapeutic areas (hematology, oncology, immune dysregulation, rare disease) with a passion for cell therapy.
Before joining Neogene, she worked at CRISPR Therapeutics for over two and half years where she lead the pivotal phase of allogeneic CD19-directed program and contributed to multiple successful INDs for potency enhanced next generation CD19 and CD70 directed allogeneic CAR programs, developed respectively in hematological malignancies and solid tumors. Prior to CRISPR, she was the clinical lead for the global phase 3 study of Mavorixafor, a small molecule CXCR4 inhibitor developed by X4 pharmaceuticals for patients with a rare primary immunodeficiency called WHIM syndrome.
Sarah earned her medical degree from the Universite Paris Descartes. She completed her residency in pediatric hematology-oncology and further trained as a fellow in clinical immunology, practicing in a university hospital setting for over 10 years. In 2017, her focus and passion for mechanism of disease targeted therapy led her to pursue a post-doctoral research fellowship at Boston’s Children’s Hospital and Harvard Medical school funded by a T32 NIH grant to dissect novel causes of primary immune deficiency.
She thrives on creating capable cross-functional teams, aligned and able to tackle complex challenges in fast paced and evolving environments, with the aim of bringing novel and transformational therapies to patients.
